Modified Cell Compositions With Microbubble Selection for Low-Loss Processing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene-modified cell therapy manufacturing processes are inefficient, costly, and lack scalability, leading to high cell loss, contamination risks, and prolonged production times, which restrict access and hinder the development of new therapies.
Innovation Solution
The AutoCell Platform (ACP) integrates advanced automation, closed-loop processing, and innovative technologies such as spinoculation and microbubble-assisted cell selection to streamline workflows, reduce cell loss, and compress production timelines, enabling high-purity, genetically modified cell production in a decentralized setting.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional manufacturing processes are used, then current production methods can be maintained, but cell loss is high (up to 92.1% T-cell loss), production time is prolonged (30-40 days), and costs are excessive
Solution Approach 1:
The patent replaces conventional mechanical separation methods (flow sorters, magnetic bead systems) with an automated platform using acoustic or electric field-based cell manipulation. This substitution eliminates the need for physical contact between cells and separation media, reducing cell loss while maintaining high purity separation. The automated system uses non-contact forces to manipulate and separate cells, achieving both high productivity and minimal cell loss.
Solution Approach 2:
The platform enables cells to be processed in their native state without requiring ex-vivo expansion steps. The system is designed to work with the cell population as received, performing separation, genetic modification, and formulation in a streamlined sequence. This self-service approach eliminates redundant steps that cause cell loss and extends production timelines.
2Reliability
If multiple antiquated equipment and processes are used, then current workflows can be maintained, but contamination risk increases and manufacturing complexity increases
Solution Approach 1:
The patent merges multiple separate processing steps (cell separation, washing, genetic modification, formulation) into a single integrated automated platform. This consolidation reduces the number of interfaces between different equipment systems, minimizing contamination risks while simplifying the overall manufacturing process. The unified system maintains reliable operation through automated protocols that eliminate manual transfer steps between different devices.
3Quantity of substance
If ex-vivo expansion steps are added to recover cell populations, then cell loss can be compensated, but production time increases and cell exhaustion occurs
Solution Approach 1:
The platform performs high-efficiency separation and recovery of target cells before genetic modification, maximizing the yield of viable cells for subsequent processing. By optimizing the separation step to recover nearly all target cells with minimal loss, the system eliminates the need for time-consuming ex-vivo expansion steps. The preliminary action of efficient separation ensures sufficient cell population for therapy without requiring additional culture time that would lead to cell exhaustion.
4Productivity
If centralized manufacturing is used, then production capacity can be increased, but logistical complexity increases and cell viability decreases
Solution Approach 1:
The automated platform is designed as a universal system that can process multiple cell types and perform all necessary manufacturing steps in one location. This multi-functional capability enables decentralized manufacturing at smaller facilities, reducing the need for complex centralized production networks. The same platform can handle different cell therapies locally, simplifying logistics while maintaining production capacity through standardized automated processes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ACP achieves efficient, cost-effective, and scalable production of gene-modified cells, reducing manufacturing costs by an order of magnitude, enhancing accessibility, and accelerating the development and delivery of advanced therapies.
Implementation Method 1
a centrifugal separation system to separate target cells from non-target cells in blood or blood products
Implementation Method 2
spinoculation and microbubble-assisted cell selection to streamline workflows
Data Source
AI summary
The invention relates to a cell solution and composition optimized for selective isolation, genetic modification, and therapeutic use of target cells, such as T-cells, NK-cells, or hematopoietic stem cells. The solution comprises at least 90% target cells, with a minimum of 75% genetically modified cells, achieving high purity and viability rates through a functionally closed system. The method incorporates microbubble-based cell selection using lipid-shell microbubbles functionalized with antibodies or aptamers for high-affinity binding. The microbubbles enable buoyant separation under centrifugal force, with reversible binding mechanisms allowing for controlled cell release. The genetically modified cells exhibit functional transgene expression and retain therapeutic efficacy, including cytokine production upon activation. Additionally, the composition minimizes contaminants such as non-target cells or microbubble fragments, ensuring suitability for downstream therapeutic applications. This innovation supports high-efficiency, contamination-free cell processing for advanced immunotherapies and regenerative medicine.